Document Detail

Acute pressor and hormonal effects of beta-endorphin at high doses in healthy and hypertensive subjects: role of opioid receptor agonism.
MedLine Citation:
PMID:  15956086     Owner:  NLM     Status:  MEDLINE    
CONTEXT: The opioid system is involved in blood pressure regulation in both normal humans and patients with essential hypertension. OBJECTIVE: The objective of the study was to investigate the effects of a high-dose infusion of beta-endorphin, an opioid peptide, on blood pressure and on the hormonal profile in healthy subjects and in hypertensive patients and the mediation played by opioid receptor agonism. DESIGN, SETTING, AND PARTICIPANTS: According to a randomized double-blind design, 11 healthy subjects (controls) and 12 hypertensive inpatients (mean age, 38.9 and 40.4 yr, respectively) received 1-h iv infusion of beta-endorphin (250 mug/h) and, on another occasion, the same infusion protocol preceded by the opioid antagonist naloxone (8 mg). MAIN OUTCOME MEASURES: Hemodynamic and hormonal measurements were performed at established times during the infusion protocols. RESULTS: At baseline, circulating beta-endorphin, norepinephrine, and endothelin-1 in hypertensive patients were significantly (P < 0.05) higher than in controls. In controls, beta-endorphin reduced blood pressure (P < 0.01) and circulating norepinephrine (P < 0.02) and increased plasma atrial natriuretic factor (P < 0.003) and GH (P < 0.0001). In hypertensive patients, beta-endorphin decreased systemic vascular resistance (P < 0.0001), blood pressure (P < 0.0001), and plasma norepinephrine (P < 0.0001) and endothelin-1 (P < 0.0001) and raised circulating atrial natriuretic factor (P < 0.0001), GH (P < 0.0001), and IGF-I (P < 0.0001). These hemodynamic and hormonal responses to beta-endorphin in hypertensive patients were significantly (P < 0.0001) greater than in controls but were annulled in all individuals when naloxone preceded beta-endorphin infusion. CONCLUSIONS: High doses of beta-endorphin induce hypotensive and beneficial hormonal effects in humans, which are enhanced in essential hypertension and are mediated by opioid receptors.
Domenico Cozzolino; Ferdinando C Sasso; Donato Cataldo; Domenico Gruosso; Armando Giammarco; Antonella Cavalli; Cristiana Di Maggio; Giuseppe Renzo; Teresa Salvatore; Dario Giugliano; Roberto Torella
Related Documents :
6991196 - Antihypertensive and hemodynamic effects of oxprenolol versus propranolol.
24293556 - Evidence-based prevention of pressure ulcers in the intensive care unit.
7246746 - Role of vasopressin, catecholamines, and plasma volume in hypertonic saline-induced hyp...
6335336 - Effect of beta-blockade on thallium-201 dipyridamole myocardial scintigraphy.
2958136 - Model dependent behaviour of pressure hypertrophied myocardium.
22063406 - High pressure applied to frozen ham at different process stages. 1. effect on the final...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial     Date:  2005-06-14
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  90     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-09-08     Completed Date:  2005-10-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5167-74     Citation Subset:  AIM; IM    
Cardiovascular Research Center, II University of Naples, via Pansini, 5, 80131 Napoli, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects*
Dose-Response Relationship, Drug
Double-Blind Method
Hemodynamics / drug effects
Hormones / blood*
Hypertension / blood,  drug therapy*,  physiopathology*
Middle Aged
Naloxone / pharmacology
Narcotic Antagonists / pharmacology
Receptors, Opioid / agonists*,  antagonists & inhibitors
beta-Endorphin / administration & dosage*,  therapeutic use
Reg. No./Substance:
0/Hormones; 0/Narcotic Antagonists; 0/Receptors, Opioid; 465-65-6/Naloxone; 60617-12-1/beta-Endorphin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone ...
Next Document:  Increased density of ghrelin-expressing cells in the gastric fundus and body in Prader-Willi syndrom...